Skip to main content

ARS Pharmaceuticals, Inc (SPRY) Stock

ARS Pharmaceuticals, Inc Stock Details, Movements and Public Alerts

Stock Details

ARS Pharmaceuticals, Inc (SPRY), a prominent company in the healthcare sector within the biotechnology industry, is based in USA and primarily trades on the NASDAQ.Currently, the stock is trading at $9.53. Over the past 52 weeks, it has ranged between $8.05 and $18.90. This places the current price at 50.4% of its 52-week high and 18.4% above its 52-week low. Recent trading volume was recorded at 2,641,599. The 14-day Relative Strength Index (RSI) stands at 33.01, suggesting neutral conditions. The stock is currently trading below its 50-day moving average of $10.05 by 5.17%. Similarly, it is below its 200-day moving average of $13.24 by 28.02%. The MACD histogram is -0.07, indicating bearish momentum (MACD Line: -0.57, Signal Line: -0.49). There are currently 2 active alerts set for SPRY by users.

52-Week Range

$18.90 - $8.05

-49.58% from high · +18.39% from low

Avg Daily Volume

1,710,236

20-day average

100-day avg: 2,154,134

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

N/A

Price to Book

5.28

EV/EBITDA

-9.88

EPS (TTM)

-$0.48

Price to Sales

7.58

Beta

0.84

Less volatile than market

How is SPRY valued relative to its earnings and growth?
Valuation data is not available for this stock.
What is SPRY's risk profile compared to the market?
With a beta of 0.84, ARS Pharmaceuticals, Inc is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 5.28 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

-42.70%

Operating Margin

-303.00%

EBITDA

$-58,733,000

Return on Equity

-23.60%

Return on Assets

-13.90%

Revenue Growth (YoY)

3043.00%

Earnings Growth (YoY)

0.00%

How profitable and efficient is SPRY's business model?
ARS Pharmaceuticals, Inc achieves a profit margin of -42.70%, meaning it retains $-42.70 from every $100 in revenue after all expenses. This relatively low margin suggests the company operates in a competitive environment or high-cost industry where profitability is challenging. The operating margin of -303.00% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at -23.60% and ROA at -13.90%, the company achieves moderate returns on invested capital.
What are SPRY's recent growth trends?
ARS Pharmaceuticals, Inc's revenue grew by 3043.00% year-over-year, representing robust expansion that significantly outpaces typical market growth rates. This strong top-line performance suggests the company is successfully capturing market share or benefiting from favorable industry trends.0 These growth metrics should be evaluated against BIOTECHNOLOGY industry averages for proper context.

Company Size & Market

Market Cap

$851.9M

Revenue (TTM)

$112.34M

Revenue/Share (TTM)

$1.15

Shares Outstanding

98.83M

Book Value/Share

$1.95

Asset Type

Common Stock

What is SPRY's market capitalization and position?
ARS Pharmaceuticals, Inc has a market capitalization of $851.9M, classifying it as a small-cap stock (under $2B). Small-caps offer significant growth potential but come with higher volatility and risk. They can be more sensitive to economic conditions but may provide outsized returns if successful. With 98.83M shares outstanding, the company's ownership is relatively concentrated. As a participant in the BIOTECHNOLOGY industry, it competes with other firms in this sector.
How does SPRY's price compare to its book value?
ARS Pharmaceuticals, Inc's book value per share is $1.95, while the current stock price is $9.53, resulting in a price-to-book (P/B) ratio of 4.89. This high P/B ratio indicates significant intangible assets, strong brand value, or high growth expectations. Technology and consumer brand companies often trade at elevated P/B ratios due to intellectual property and competitive advantages not reflected on the balance sheet. As a common stock, this represents equity ownership with voting rights.

Analyst Ratings

Analyst Target Price

$31.33

228.75% upside potential

Analyst Recommendations

Strong Buy

1

Buy

5

Hold

0

Sell

0

Strong Sell

0

How reliable are analyst predictions for SPRY?
6 analysts cover SPRY with 100% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The strong bullish consensus may already be priced in. The consensus target of $31.33 implies 228.8% upside, but targets are often adjusted to follow price moves rather than predict them.
What is the Wall Street consensus on SPRY?
Current analyst recommendations:1 Strong Buy, 5 Buy, 000The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Nov 1, 2025, 02:10 AM

Technical Indicators

RSI (14-day)

33.01

Neutral

50-Day Moving Average

$10.05

-5.17% below MA-50

200-Day Moving Average

$13.24

-28.02% below MA-200

MACD Line

-0.57

MACD Signal

-0.49

MACD Histogram

-0.07

Bearish

What does SPRY's RSI value tell investors?
The RSI (Relative Strength Index) for SPRY is currently 33.01, indicating the stock is showing bearish momentum (30-40 range). Selling pressure is evident but not extreme. This often occurs during pullbacks in uptrends or early stages of downtrends. Combined with the price being below the 50-day moving average, this confirms bearish conditions.
How should traders interpret SPRY's MACD and moving average crossovers?
MACD analysis shows the MACD line at -0.57 below the signal line at -0.49, with histogram at -0.07. This bearish crossover indicates downward pressure. The narrow histogram suggests a potential trend change ahead. The 50-day MA ($10.05) is below the 200-day MA ($13.24), forming a death cross pattern that often warns of extended weakness. Price is currently below both MAs, confirming weakness.

Indicators last updated: Nov 7, 2025, 12:34 AM

Active Alerts

Alert Condition
Price rises above
Threshold
$31.33
Created
Nov 10, 2025, 03:34 PM
Alert Condition
RSI Threshold Cross
Threshold
30
Created
Nov 10, 2025, 03:34 PM

Stay Ahead of the Market with ARS Pharmaceuticals, Inc Alerts

Set up price alerts for ARS Pharmaceuticals, Inc and get notified instantly when the price hits your target. Never miss an important price movement again.